12.

Information about Geographic Areas

The Company operates as a single reportable segment and primarily enables customers to perform both research and clinical testing on its nCounter Analysis System. The Company has one sales force that sells these systems to both research and clinical testing labs, and has launched its first product, nCounter Elements reagents, that can be used for both research and diagnostic testing. In addition, the Company’s Prosigna Breast Cancer Assay is marketed to clinical laboratories. The Company has also entered into a companion diagnostic collaboration with Celgene Corporation.

The following table of total revenue is based on the geographic location of the Company’s customers, distributors and collaborator. For sales to distributors, their geographic location may be different from the geographic locations of the ultimate end user. Total revenue by geography was as follows (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013

North America	$	7,387	$	5,218	$	13,376	$	9,695
Europe & Middle East		2,130		1,494		3,893		2,110
Asia Pacific		1,364		506		2,363		1,089

Total revenue	$	10,881	$	7,218	$	19,632	$	12,894

Total revenue in the United States was $6.9 million, $4.3 million, $12.2 million and $7.9 million for the three and six month periods ended June 30, 2014 and 2013, respectively.

Substantially all of the Company’s assets, including long-lived assets, are located in the United States.